RxDoctor Payments Data

Sherry Kuo, DO

Pulmonary Disease · Grand Rapids, MINPI 1184839011

Payments from drug & device makers

$30,163in general payments, 2019–2025

Across 133 payments — averaging $226.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$27K
  • GSK$549
  • Boehringer Ingelheim$375
  • Actelion Pharmaceuticals US, Inc.$368
  • Grifols USA, LLC$273
  • Sanofi$239
  • plus $892 from 12 others

What the payments were for

  • Consulting fees$7,99326%
  • Speaking & faculty fees$16,30054%
  • Travel & lodging$2,2097%
  • Food & beverage$3,56112%
  • Education$1000%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$30,163 in reported general payments places this provider in the 85th percentile of 463 pulmonary disease providers in Michigan.

See all pulmonary disease providers in Michigan

Medicare billing

Part B allowed, 2024
$41,059
Medicare patients
223
Services billed
585

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter343$262,515
Breztri AerosphereBudesonide/Glycopyr/Formoterol265$211,569
OfevNintedanib Esylate14$161,573
TezspireTezepelumab-Ekko22$85,766
Spiriva RespimatTiotropium Bromide36$28,049
Stiolto RespimatTiotropium Br/Olodaterol Hcl46$20,057
Breo ElliptaFluticasone/Vilanterol35$17,179
Fluticasone-SalmeterolFluticasone Propion/Salmeterol98$15,420
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate29$13,973
DuleraMometasone/Formoterol19$13,147
Bevespi AerosphereGlycopyrrolate/Formoterol Fum26$12,732
Qvar RedihalerBeclomethasone Dipropionate33$9,487
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr13$8,916
Albuterol Sulfate HfaAlbuterol Sulfate244$8,499
Incruse ElliptaUmeclidinium Bromide16$7,838

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaBreztri Aerosphere, Tezspire, Bevespi Aerosphere, Symbicort, Pulmicort Flexhaler$27,467$317,970338 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta$549$296,449407 claims
Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat$375$209,67996 claims
MerckDulera$16$13,14719 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 463 pulmonary disease providers in Michigan.

Other pulmonary disease in Grand Rapids

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →